Keyphrases
Nuclear Localization
100%
Yes-associated Protein 1 (YAP1)
100%
Protein Tyrosine Phosphorylation
100%
Cholangiocarcinoma Cells
100%
Phosphorylation
45%
Patient-derived Xenograft
27%
Cholangiocarcinoma
27%
Tyrosine Phosphorylation
27%
Dasatinib
18%
Src Kinase
18%
Protein Regulation
18%
LATS1
18%
Relay Module
9%
Expression Level
9%
Tyrosine
9%
Small Interfering RNA (siRNA)
9%
Serine-threonine Kinase
9%
Transcriptional Repressor
9%
Therapeutic Efficacy
9%
Target Gene Expression
9%
Resection
9%
Site-directed mutagenesis
9%
Kinase Inhibition
9%
Clinical Observation
9%
Cas9 Protein
9%
Protein mutants
9%
Protein Targeting
9%
Cholangiocarcinoma Cell Line
9%
Cell Line-derived Xenograft
9%
Hippo Pathway
9%
Serine Residues
9%
Cytoplasmic Sequestration
9%
MST1
9%
Early Tumor Recurrence
9%
Cell-derived Xenograft
9%
Medicine and Dentistry
Cholangiocarcinoma
100%
Protein Phosphorylation
100%
Long Acting Thyroid Stimulator
100%
Xenograft
60%
Serine
40%
Dasatinib
40%
SRC-Family Kinase
40%
Cell Line
20%
Tumor Recurrence
20%
Gene Expression
20%
Combination Therapy
20%
Target Protein
20%
Small Interfering RNA
20%
Clinical Observation
20%
Cas9
20%
Clustered Regularly Interspaced Short Palindromic Repeat
20%
Mutant Protein
20%
Cholangiocarcinoma Cell Line
20%
Site-Directed Mutagenesis
20%
Alanine
20%
Protein Serine Threonine Kinase
20%
Biochemistry, Genetics and Molecular Biology
Tyrosine Phosphorylation
100%
Serine
75%
Dasatinib
50%
Src Family Kinase
50%
Kinase
25%
Phosphotransferase
25%
Tyrosine
25%
Gene Expression
25%
Mutant Protein
25%
Site-Directed Mutagenesis
25%
CRISPR/Cas9
25%
Small Interfering RNA
25%
MST1
25%
Threonine
25%
Alanine
25%
Immunology and Microbiology
Protein Phosphorylation
100%
Xenograft
75%
Serine
75%
Cell Line
25%
Gene Expression
25%
CRISPR/Cas9
25%
Site Directed Mutagenesis
25%
Cholangiocarcinoma Cell Line
25%
Tyrosine
25%
Threonine
25%
Alanine
25%
Pharmacology, Toxicology and Pharmaceutical Science
Bile Duct Carcinoma
100%
Long Acting Thyroid Stimulator
100%
Phosphotransferase
33%
Serine
33%
Dasatinib
33%
Combination Therapy
16%
Mutant Protein
16%
Protein Serine Threonine Kinase
16%
Tumor Recurrence
16%
Small Interfering RNA
16%
Site-Directed Mutagenesis
16%
Alanine
16%